The 6th Annual iPSC Drug Development Summit focuses on iPSC drug development, advancing stem cell–derived therapies, and translating pluripotent cell technologies into scalable, clinically and commercially viable treatments.
Key topics
Pipeline-to-patient translation and clinical milestone development for iPSC therapies
Allogeneic and autologous iPSC engineering strategies for next-generation cell therapies
GMP-compatible gene editing and scalable iPSC manufacturing approaches
AI-driven genetic programming for cell fate control and discovery acceleration
iPSC-derived dopaminergic neuron and progenitor therapies for neurological diseases
Ocular iPSC-derived cell therapies and retinal organoid development for vision restoration
Quality control, regulatory frameworks, and global harmonization for iPSC development
Cell line selection, donor optimization, and reduction of manufacturing variability
Preclinical evaluation frameworks and safety strategies for iPSC-based therapies
Commercial readiness, scalability, and investment alignment for iPSC programs
Manufacturing scale-up strategies including CAR-NK and off-the-shelf cell products
Who should attend
Stem cell and regenerative medicine researchers
iPSC drug development scientists and translational biologists
Cell therapy manufacturing and process development specialists
Regulatory affairs and clinical development professionals
Biotech investors and pharmaceutical strategy leaders
Gene editing and cellular engineering experts
Venue
Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, United States
